Catherine Oakley presents the National Chemotherapy Board Good Practice Guideline for promoting early identification of systemic anti-cancer therapies side effects

I represent UKONS on the National Chemotherapy Board, which has a remit to provide guidance, oversight and support for the continued development of high-quality, systemic anti-cancer therapies for cancer patients. The Board is attended by members involved in the delivery of systemic anticancer therapies and includes the Association of Cancer Physicians, the Royal College of Radiologists, Joint Speciality Committee of the Royal College of Physicians, the Royal College of Pathologists, UKONS, British Oncology Pharmacy Association, Public Health England SACT, NHS England Clinical Reference Group and lay representatives.